| Date | Article |
|---|
| May 21, 2018 |  FDA Approves Prolia (denosumab) for Glucocorticoid-Induced Osteoporosis |
| Sep 21, 2012 | FDA Approves New Indication For Prolia (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture |
| Sep 19, 2011 | FDA Approves New Indications for Prolia (denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy |
| Jun 1, 2010 | FDA Approves Amgen's Prolia (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture |
| May 17, 2010 | Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients |
| Oct 21, 2009 | Amgen Provides Update on Status of Prolia (denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA) |
| Aug 14, 2009 | Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting |
| Feb 18, 2009 | FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab |
| Dec 22, 2008 | Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer |